Beta Bionics vs Kestra Medical Technologies
BBNX and KMTS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BBNX and KMTS compare
Kestra Medical Technologies is the larger company, worth 1.9 times as much as Beta Bionics ($1.7B against $893M).
Kestra Medical Technologies grew revenue faster over the last twelve months (60.7% versus 43.7% for Beta Bionics).
Beta Bionics keeps more of each dollar of sales as profit, with a net margin of −65.3% compared with −140% at Kestra Medical Technologies.
Beta Bionics scores higher on the StockData Score (10 against 5 for Kestra Medical Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BBNX | KMTS |
|---|---|---|
| Size and price | ||
| Market cap | $893M | $1.7B |
| Share price | $16.42 | $28.64 |
| Change, 1 year | −41.7% | 6.9% |
| Beta (5Y) | 1.28 | 1.21 |
| Employees | 420 | 443 |
| StockData Score | ||
| Total score | 10 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.0× (better) | 16.0× |
| P/B | 2.2× | – |
| FCF yield | −7.4% | −7.2% (better) |
| Fair value | $15.49 | – |
| Margin of safety | −6.0% | – |
| Growth | ||
| Revenue growth (TTM) | 43.7% | 60.7% (better) |
| Profitability | ||
| Gross margin | 58.6% (better) | 53.9% |
| Operating margin | −72.7% (better) | −134% |
| Net margin | −65.3% (better) | −140% |
| FCF margin | −51.8% (better) | −115% |
| Return on equity | −23.9% | – |
| Return on invested capital | −64.4% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −19.0× |
| Current ratio | 8.92 (better) | 4.69 |
| Altman Z-score | 11.55 (better) | 4.94 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 88.2% | 98.6% |
| Held by insiders | 9.3% | 44.0% |
| Insider net buying, 12 months | −$5.4M (better) | −$15.3M |
| Short interest, % of float | 10.1% | 12.3% |
Go deeper
- BBNX stock overview
- BBNX income statement
- BBNX valuation and score
- KMTS stock overview
- KMTS income statement
- KMTS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.